1. Key Insights

2. Vasomotor Symptoms (Hot Flashes/Night Sweats): Market Overview at a Glance
2.1. Total Market Share (%) Distribution of Vasomotor Symptoms (Hot Flashes/Night Sweats) in 2017
2.2. Total Market Share (%) Distribution of Vasomotor Symptoms (Hot Flashes/Night Sweats) in 2030

3. Executive summary

4. Organizations

5. Epidemiology and Market Methodology

6. Vasomotor Symptoms (VMS) associated with menopause: Disease Background and Overview
6.1. Introduction
6.2. Vasomotor Symptoms (Hot Flashes/Night Sweats)
6.3. Signs and Symptoms of VMS
6.4. Pathophysiology of VMS
6.5. Risk factors for VMS
6.6. Effects of VMS
6.7. Premature (early) Menopause
6.8. Menopause Associated with Breast Cancer Treatment

7. Epidemiology and Patient Population
7.1. Key Findings

8. Total Prevalent cases of Vasomotor Symptoms (Hot Flashes/Night Sweats) in Post-menopause in 7MM

9. Country Wise-Epidemiology of Hot Flashes Associated with Post-menopause
9.1. United States
9.1.1. Assumptions and Rationale
9.1.2. Total Prevalent Population of Vasomotor Symptoms (Hot Flashes/Night Sweats) Associated with Post-menopause in the United States
9.1.3. Severity-Specific cases of Hot Flashes in Post-menopause in the United States
9.2. EU5 Countries
9.3. Germany
9.3.1. Assumptions and Rationale
9.3.2. Total Prevalent Population of Vasomotor Symptoms (Hot Flashes/Night Sweats) Associated with Post-menopause in Germany
9.3.3. Severity-Specific cases of Hot Flashes in Post-menopause in the Post-menopause in Germany
9.4. France
9.4.1. Assumptions and Rationale
9.4.2. Total Prevalent Population of Vasomotor Symptoms (Hot Flashes/Night Sweats) Associated with Post-menopause in France
9.4.3. Severity-Specific cases of Hot Flashes in Post-menopause in the with Post-menopause in France
9.5. Italy
9.5.1. Assumptions and Rationale
9.5.2. Total Prevalent Population of Vasomotor Symptoms (Hot Flashes/Night Sweats) Associated with Post-menopause in Italy
9.5.3. Severity-Specific cases of Hot Flashes in Post-menopause in the Post-menopause in Italy
9.6. Spain
9.6.1. Assumptions and Rationale
9.6.2. Total Prevalent Population of Vasomotor Symptoms (Hot Flashes/Night Sweats) Associated with Post-menopause in Spain
9.6.3. Severity-Specific cases of Hot Flashes in Post-menopause in the Post-menopause in Spain
9.7. The United Kingdom
9.7.1. Assumptions and Rationale
9.7.2. Total Prevalent Population of Vasomotor Symptoms (Hot Flashes/Night Sweats) Associated with Post-menopause in the UK
9.7.3. Severity-Specific cases of Hot Flashes in Post-menopause in the Post-menopause in the UK
9.8. Japan
9.8.1. Assumptions and Rationale
9.8.2. Total Prevalent Population of Vasomotor Symptoms (Hot Flashes/Night Sweats) Associated with Post-menopause in Japan
9.8.3. Severity-Specific cases of Hot Flashes in Post-menopause in the Post-menopause in Japan

10. Treatment Algorithm, Current Treatment, and Medical Practices
10.1. Hormonal Therapies
10.1.1. Estrogen Replacement Therapies
10.1.2. Progestational Agents
10.2. Non-hormonal pharmacological treatments for vasomotor symptoms
10.2.1. Clonidine
10.2.2. Serotonin Reuptake Inhibitors
10.2.3. Gabapentin
10.2.4. Behavioral Modifications
10.3. Complementary alternative medicines (CAM)

11. Unmet Needs

12. Marketed drugs by class
12.1. Hormonal Therapies
12.1.1. Estrogen Only Therapies
12.1.2. Combination Therapies
12.2. Non-Hormonal Therapies
12.2.1. Approved Drug
12.2.2. Off-Label Antidepressants
12.3. Recent additions in Hormonal therapies
12.4. Bijuva: TherapeuticsMD
12.4.1. Drug Description
12.4.2. Regulatory Milestones
12.4.3. Other Development Activities
12.4.4. Clinical Development
12.4.5. Safety and Efficacy
12.4.6. Product Profile

13. Emerging Therapies
13.1. Key Cross Competition
13.2. Hormonal Based therapies
13.3. Donesta: Mithra Pharmaceuticals (Donesta Biosciences)
13.3.1. Product Description
13.3.2. Other Developmental Activities
13.3.3. Clinical Development
13.3.4. Safety and Efficacy
13.3.5. Product Profile
13.4. Non-Hormonal Based therapies
13.5. NT-814: KaNDy Therapeutics
13.5.1. Product Description
13.5.2. Other Developmental Activities
13.5.3. Clinical Development
13.5.4. Safety and Efficacy
13.5.5. Product Profile
13.6. FP-101: Fervent Pharmaceuticals
13.6.1. Product Description
13.6.2. Other Developmental Activities
13.6.3. Clinical Development
13.6.4. Safety and Efficacy
13.6.5. Product Profile
13.7. Fezolinetant: Astellas Pharma
13.7.1. Drug Description
13.7.2. Other Developmental Activities
13.7.3. Clinical Development
13.7.4. Safety and Efficacy
13.7.5. Product Profile
13.8. Other Potential therapies
13.9. SJX 653: Sojournix
13.9.1. Drug Description
13.9.2. Other Developmental Activities
13.9.3. Clinical Development
13.9.4. Safety and Efficacy
13.9.5. Product Profile
13.10. MT-8554: Mitsubishi Tanabe Pharma
13.10.1. Drug Description
13.10.2. Clinical Development
13.10.3. Product Profile

14. Hot Flashes: 7 Major Market Analysis
14.1. Key Findings
14.2. Market Size of Hot Flashes associated with Post Menopause in 7MM

15. Seven Major Market Outlook
15.1. United States Market Size
15.1.1. The total market size of Hot Flashes Associated with Post-menopause in the United States
15.1.2. The total market size of Hot Flashes by Therapies in the United States
15.2. Germany
15.2.1. The total market size of Hot Flashes Associated with Post-menopause in Germany
15.2.2. The total market size of Hot Flashes by Therapies in Germany
15.3. France
15.3.1. The total market size of Hot Flashes Associated with Post-menopause in France
15.3.2. The total market size of Hot Flashes by Therapies in France
15.4. Italy
15.4.1. The total market size of Hot Flashes Associated with Post-menopause in Italy
15.4.2. The total market size of Hot Flashes by Therapies in Italy
15.5. Spain
15.5.1. Total Market Size of Hot Flashes Associated with Post-menopause in Spain
15.5.2. The total market size of Hot Flashes by Therapies in Spain
15.6. United Kingdom
15.6.1. The total market size of Hot Flashes Associated with Post-menopause in the United Kingdom
15.6.2. The total market size of Hot Flashes by Therapies in the UK
15.7. Japan
15.7.1. The total market size of Hot Flashes in Japan
15.7.2. The total market size of Hot Flashes by Therapies in Japan

16. Market Drivers

17. Market Barriers

18. SWOT

19. Case Studies
19.1. A Case Report of Hot Flashes for Menopause Awareness
19.2. A Case Report of a symptomatic patient in whom hormone therapy (HT) was abruptly stopped

20. KOL Views

21. Appendix
21.1. Report Methodology

22. DelveInsight Capabilities

23. Disclaimer

24. About DelveInsight

List of Tables
Table 1 Conditions that may cause or mimic vasomotor events and that can be distinguished from menopausal symptoms by history, examination, and investigations
Table 2 Total Prevalent cases of Vasomotor Symptoms (Hot Flashes) in Post-menopause in 7MM (2017–2030)
Table 3 Total Prevalent Population of Hot Flashes Associated with Post-menopause in the United States (2017–2030)
Table 4 Severity Specific Prevalence of Hot Flashes Associated with Post menopause in the United States (2017–2030)
Table 5 Total Prevalent Population of Hot Flashes associated with Post Menopause in Germany (2017–2030)
Table 6 Severity Specific Prevalence of Hot Flashes Associated with Post-menopause in Germany (2017–2030)
Table 7 Total Prevalent Population of Hot Flashes Associated with Post-menopause in France (2016-2027)
Table 8 Severity Specific Prevalence of Hot Flashes Associated with Post-menopause in France (2017–2030)
Table 9 Total Prevalent Population of Hot Flashes Associated with Post-menopause in Italy (2016-2027)
Table 10 Severity Specific Prevalence of Hot Flashes Associated with Post-menopause in Italy (2017–2030)
Table 11 Total Prevalent Population of Hot Flashes Associated with Post-menopause in Spain (2017-2030)
Table 12 Severity Specific Prevalence of Hot Flashes Associated with Post-menopause in Spain (2017–2030)
Table 13 Total Prevalent Population of Hot Flashes Associated with Post-menopause in the UK (2017-2030)
Table 14 Severity Specific Prevalence of Hot Flashes Associated with Post-menopause in the UK (2017–2030)
Table 15 Total Prevalent Population of Hot Flashes Associated with Post-menopause in Japan (2017–2030)
Table 16 Severity Specific Prevalence of Hot Flashes Associated with Post-menopause in Japan (2017–2030)
Table 17 Hot Flashes Treatments Algorithm
Table 18 Complementary and alternative medicines for the treatment of menopausal symptoms
Table 19 Key cross of Estrogen based Oral therapies
Table 20 Key cross of Estrogen based Transdemal Patch
Table 21 key cross of Estrogen based Transdemal Spray
Table 22 key cross of Estrogen based Transdemal gel
Table 23 key cross of Estrogen based Vaginal Ring
Table 24 Key cross of Oral combination therapies
Table 25 Key cross of Transdermal combination therapies
Table 26 Details of Non-Hormonal therapies
Table 27 Details of off-label Antidepressant therapies
Table 28 Donesta, Clinical Trial Description, 2020
Table 29 NT-814, Clinical Trial Description, 2020
Table 30 FP-101, Clinical Trial Description, 2020
Table 31 Fezolinetant, Clinical Trial Description, 2020
Table 32 MT-8554, Clinical Trial Description, 2020
Table 33 Market Size of Hot Flashes associated with Post Menopause in 7MM in USD Million (2017–2030)
Table 34 US Market Size of Hot Flashes associated with Post-menopause in USD Million (2017–2030)
Table 35 US Market Size of Hot Flashes associated with Post-menopause in USD Million (2017–2030)
Table 36 Market Size of Hot Flashes associated with Post-menopause in Germany, USD Millions (2017–2030)
Table 37 Germany Market Size of Hot Flashes associated with Post-menopause in USD Million (2017–2030)
Table 38 Market Size of Hot Flashes associated with Postmenopause in France, USD Millions (2017–2030)
Table 39 France Market Size of Hot Flashes associated with Post-menopause in USD Million (2017–2030)
Table 40 Market Size of Hot Flashes associated with Post menopause in Italy, USD Millions (2017–2030)
Table 41 Italy Market Size of Hot Flashes associated with Post-menopause in USD Million (2017–2030)
Table 42 Market Size of Hot Flashes associated with Post Menopause in Spain, USD Millions (2017–2030)
Table 43 Spain Market Size of Hot Flashes associated with Post-menopause in USD Million (2017–2030)
Table 44 Market Size of Hot Flashes associated with Post Menopause in the UK, USD Millions (2017–2030)
Table 45 UK Market Size of Hot Flashes associated with Post-menopause in USD Million (2017–2030)
Table 46 Market Size of Hot Flashes associated with Post Menopause in Japan, USD Millions (2017–2030)
Table 47 Japan Market Size of Hot Flashes associated with Post-menopause in USD Million (2017–2030)

List of Figures
Figure 1 Epidemiology and Market Methodology
Figure 2 Stages of menopause
Figure 3 Vasomotor Symptoms
Figure 4 The 3 major components involved in thermoregulatory function.
Figure 5 Relationship between estrogen and a woman’s reproductive phases and the occurrence of hot flashes.
Figure 6 Maintenance of core body temperature (CBT) is critical to organ integrity and optimal function.
Figure 7 Relationship between estrogen and a woman’s reproductive phases and the occurrence of hot flashes.
Figure 8 Risk factors for VMS
Figure 9 Effects of VMS
Figure 10 Impact of VMS on QOL
Figure 11 Breast Cancer therapies causing Menopause
Figure 12 Total Prevalent cases of Vasomotor Symptoms (Hot Flashes) in Post-menopause in 7MM (2017–2030)
Figure 13 Prevalence of Hot Flashes Associated with Post menopause in the United States (2017–2030)
Figure 14 Severity Specific Prevalence of Hot Flashes associated with Post-menopause in the US (2017–2030)
Figure 15 Prevalence of Hot Flashes associated with Post Menopause in Germany (2017–2030)
Figure 16 Severity Specific Prevalence of Hot Flashes Associated with Post-menopause in Germany (2017–2030)
Figure 17 Prevalence of Hot Flashes Associated with Post-menopause in France (2017–2030)
Figure 18 Severity Specific Prevalence of Hot Flashes Associated with Post-menopause in France (2017–2030)
Figure 19 Prevalence of Hot Flashes Associated with Post-menopause in Italy (2017–2030)
Figure 20 Severity Specific Prevalence of Hot Flashes Associated with Post-menopause in Italy (2017–2030)
Figure 21 Prevalence of Hot Flashes Associated with Post-menopause in Spain (2017–2030)
Figure 22 Severity Specific Prevalence of Hot Flashes Associated with Post-menopause in Spain (2017–2030)
Figure 23 Prevalence of Hot Flashes Associated with Post-menopause in the UK (2017–2030)
Figure 24 Severity Specific Prevalence of Hot Flashes Associated with Post-menopause in the UK (2017–2030)
Figure 25 Prevalence of Hot Flashes Associated with Post-menopause in Japan (2017–2030)
Figure 26 Severity Specific Prevalence of Hot Flashes Associated with Post-menopause in Japan (2017–2030)
Figure 27 Non-hormonal pharmacological treatments for vasomotor symptoms
Figure 28 Unmet Needs of Hot Flashes
Figure 29 Market Size of Hot Flashes associated with post menopause in USD Million (2017–2030)
Figure 30 Market Size of Hot Flashes associated with Post-menopause in the US, USD Millions (2017–2030)
Figure 31 Market Size of Hot Flashes associated with Post-menopause in the US by therapies, USD Millions (2017–2030)
Figure 32 Market Size of Hot Flashes associated with Post-menopause in Germany, USD Millions (2017–2030)
Figure 33 Market Size of Hot Flashes associated with Post-menopause in Germany by therapies, USD Millions (2017–2030)
Figure 34 Market Size of Hot Flashes associated with Post-menopause in France, USD Millions (2017–2030)
Figure 35 Market Size of Hot Flashes associated with Post-menopause in France by therapies, USD Millions (2017–2030)
Figure 36 Market Size of Hot Flashes associated with Post menopause in Italy, USD Millions (2017–2030)
Figure 37 Market Size of Hot Flashes associated with Post-menopause in Italy by therapies, USD Millions (2017–2030)
Figure 38 Market Size of Hot Flashes associated with Post Menopause in Spain, USD Millions (2017–2030)
Figure 39 Market Size of Hot Flashes associated with Post-menopause in Spain by therapies, USD Millions (2017–2030)
Figure 40 Market Size of Hot Flashes associated with Post Menopause in the UK, USD Millions (2017–2030)
Figure 41 Market Size of Hot Flashes associated with Post-menopause in the UK by therapies, USD Millions (2017–2030)
Figure 42 Market Size of Hot Flashes associated with Post Menopause in Japan, USD Millions (2017–2030)
Figure 43 Market Size of Hot Flashes associated with Post-menopause in Japan by therapies, USD Millions (2017–2030)
Figure 44 Market Drivers
Figure 45 Market Barriers